UA93387C2 - Pyrimidine derivatives and their use as kcnq potassium channels openers - Google Patents

Pyrimidine derivatives and their use as kcnq potassium channels openers

Info

Publication number
UA93387C2
UA93387C2 UAA200803570A UAA200803570A UA93387C2 UA 93387 C2 UA93387 C2 UA 93387C2 UA A200803570 A UAA200803570 A UA A200803570A UA A200803570 A UAA200803570 A UA A200803570A UA 93387 C2 UA93387 C2 UA 93387C2
Authority
UA
Ukraine
Prior art keywords
pyrimidine derivatives
potassium channels
kcnq potassium
openers
channels openers
Prior art date
Application number
UAA200803570A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Николай Ханжин
Даниэль Родригес Греве
Марио Роттлондер
Original Assignee
X. Луннбэк A/C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X. Луннбэк A/C filed Critical X. Луннбэк A/C
Publication of UA93387C2 publication Critical patent/UA93387C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pyrimidine derivatives of the general formula I or salts thereof and their use as openers of the KNCQ family potassium ion channels, particularly in the treatment of epilepsy.(I)
UAA200803570A 2005-09-09 2006-09-07 Pyrimidine derivatives and their use as kcnq potassium channels openers UA93387C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200501262 2005-09-09

Publications (1)

Publication Number Publication Date
UA93387C2 true UA93387C2 (en) 2011-02-10

Family

ID=37199174

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200803570A UA93387C2 (en) 2005-09-09 2006-09-07 Pyrimidine derivatives and their use as kcnq potassium channels openers

Country Status (15)

Country Link
EP (1) EP1937653A1 (en)
JP (1) JP2009507052A (en)
KR (1) KR20080043314A (en)
CN (1) CN101258133A (en)
AR (1) AR055420A1 (en)
AU (1) AU2006322461A1 (en)
BR (1) BRPI0615631A2 (en)
CA (1) CA2621854A1 (en)
EA (1) EA200800780A1 (en)
IL (1) IL189545A0 (en)
MX (1) MX2008002294A (en)
NO (1) NO20081713L (en)
UA (1) UA93387C2 (en)
WO (1) WO2007065449A1 (en)
ZA (1) ZA200802174B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201070189A1 (en) * 2007-08-01 2010-08-30 Х. Лундбекк А/С USE OF COMPOUNDS, OPENING KCNQ CALIUM CHANNELS, TO SUPPRESS SYMPTOMS OR TREATMENT OF DISORDERS OR CONDITIONS, WHICH DOPAMINERGICAL SYSTEM IS DAMAGED
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2010097379A1 (en) * 2009-02-24 2010-09-02 Neurosearch A/S Substituted pyrimidin derivatives and their medical use
JP5763758B2 (en) * 2010-07-08 2015-08-12 ファイザー・インク Piperidinyl pyrimidineamide as a Kv7 potassium channel opener
EP3318556A1 (en) * 2010-10-20 2018-05-09 Grünenthal GmbH Substituted 6-amino-nicotinamides as kcnq2/3 modulators
CN103508943B (en) * 2012-06-29 2017-06-09 江苏先声药业有限公司 As the compound of potassium channel modulating agents
CN103508960B (en) * 2012-06-29 2017-12-12 江苏先声药业有限公司 Benzheterocyclic derivatives
KR20170076673A (en) * 2014-10-24 2017-07-04 오노 야꾸힝 고교 가부시키가이샤 Kcnq2-5 channel activator
WO2021023616A1 (en) * 2019-08-02 2021-02-11 H. Lundbeck A/S Alcohol derivatives as kv7 potassium channel openers for use in epilepsy or seizures

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361879A1 (en) * 2001-02-20 2003-11-19 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
AU2003202115A1 (en) * 2002-02-12 2003-09-04 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
US20080261918A1 (en) * 2004-12-17 2008-10-23 Graham Andrew Showell Silicon Compounds and Their Use

Also Published As

Publication number Publication date
ZA200802174B (en) 2009-10-28
AR055420A1 (en) 2007-08-22
IL189545A0 (en) 2008-06-05
BRPI0615631A2 (en) 2011-05-24
EP1937653A1 (en) 2008-07-02
AU2006322461A1 (en) 2007-06-14
WO2007065449A1 (en) 2007-06-14
MX2008002294A (en) 2008-03-14
JP2009507052A (en) 2009-02-19
CN101258133A (en) 2008-09-03
EA200800780A1 (en) 2008-06-30
CA2621854A1 (en) 2007-06-14
NO20081713L (en) 2008-06-04
KR20080043314A (en) 2008-05-16

Similar Documents

Publication Publication Date Title
UA93387C2 (en) Pyrimidine derivatives and their use as kcnq potassium channels openers
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2007027238A3 (en) Jak kinase inhibitors and their uses
SG164368A1 (en) Treatment of cancer
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
TW200630367A (en) Substituted adenines and the uses thereof
UA85559C2 (en) Aminobenzophenone compounds
MX2010004576A (en) Novel pyrimidine derivatives.
TW200624426A (en) BACE inhibitors
TW200700064A (en) Novel compounds
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
UA102251C2 (en) Aminidihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
EA200700633A1 (en) DERIVATIVES OF THE SUBSTITUTED ANILINE
WO2009077471A3 (en) Azolylmethyloxiranes, use thereof and agents containing the same
IL190730A0 (en) Potassium channel inhibitors
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
MX2009013515A (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics.
UA84954C2 (en) Fused pyrimidones usefuel in the treatment and the prevention of cancer
MX2009007713A (en) Pyridazine derivatives, processes for their preparation and their use as fungicides.
PL1937669T3 (en) Novel benzopyran derivatives as potassium channel openers
WO2007120333A3 (en) Tetracyclic kinase inhibitors
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
TW200726763A (en) Novel compound
MX2010009276A (en) Pyrrolopyrimidinecarboxamides.
MX2009009490A (en) Novel prodrugs.